Mechanism of action and resistance to Trastuzumab Deruxtecan in patients with metastatic breast cancer: the DAISY trial

Fabrice André, Fernanda Mosele, Élise Deluche, Amélie Lusque, Loic Le-Bescond, Thomas Filleron, Yoann Pradat, Agnès Ducoulombier, Barbara Pistilli, Thomas Bachelot, F. Viret, Christelle Lévy, Nicolas Signolle, Alexia Alfaro, D. Tran, Ingrid Garberis, Hugues Talbot, Stergios Christodoulidis, Maria Vakalopoulou, Nathalie Droin, Aurelie Stourm, Maki Kobayashi, Tomaya Kakegawa, Ludovic Lacroix, Patrick Saulnier, Bastien Job, Marc Deloger, Marta Jimenez, Vianney Baris, Pierre Laplante, Patricia Kannouche, Virginie Marty, Magali Lacroix‐Triki, Véronique DièrasResearch Square 2022 · DOI

Introduction

Trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate (ADC) targeting HER2, has significantly improved outcomes for patients with metastatic breast cancer (mBC). While its efficacy in HER2-overexpressing and HER2-low tumors is well-documented, the biological drivers of response in patients with no detectable HER2 expression and the mechanisms underlying acquired resistance have remained elusive. The DAISY trial (NCT04132960) was designed to address these gaps by evaluating T-DXd across the full spectrum of HER2 expression and utilizing deep molecular profiling to uncover the drug's mechanism of action and resistance.

Study Design and Methodology

This Phase II, open-label study enrolled 186 patients with mBC who had progressed after at least one line of chemotherapy. Patients were stratified into three cohorts based on HER2 immunohistochemistry (IHC) and in situ hybridization (ISH) status:

  • Cohort 1 (HER2-overexpressing): IHC 3+ or IHC 2+/ISH+ (n = 72)
  • Cohort 2 (HER2-low): IHC 2+/ISH- or IHC 1+ (n = 74)
  • Cohort 3 (HER2 IHC 0): No detectable HER2 (n = 40)

The research team employed a multi-omic approach, including whole-exome sequencing (WES) of baseline and progression biopsies, AI-powered spatial analysis of HER2 distribution, and digital spatial profiling (GeoMx) to characterize the tumor microenvironment (TME).

Clinical Efficacy: The HER2 Gradient

The trial demonstrated that T-DXd efficacy follows a gradient corresponding to HER2 expression levels. In the full analysis set (n = 177), the confirmed objective response rate (ORR) was:

  • 70.6% in Cohort 1
  • 37.5% in Cohort 2
  • 29.7% in Cohort 3

Progression-free survival (PFS) followed a similar trend, with a median of 11.1 months for HER2-overexpressing tumors, 6.7 months for HER2-low, and 4.2 months for IHC 0. Notably, the nearly 30% response rate in the IHC 0 cohort suggests that even "undetectable" HER2 levels may be sufficient for T-DXd activity, or that these tumors are highly sensitive to the DXd payload via the bystander effect.

Spatial Distribution and the Tumor Microenvironment

Exploratory analyses revealed that the spatial architecture of HER2 expression is a critical predictor of response. Using machine learning clustering on digitized slides, researchers found that the spatial distribution of HER2—rather than just average intensity—correlated with treatment outcomes in HER2-overexpressing mBC.

Interestingly, the study found no significant quantitative modulation of the tumor microenvironment (such as immune cell density) after 6 to 8 weeks of treatment. However, a decrease in PD-L1 expression was observed specifically in HER2-overexpressing tumors, suggesting a localized immunomodulatory effect.

Uncovering Secondary Resistance: The Role of SLX4

A major contribution of the DAISY trial is the identification of SLX4 mutations as a potential mediator of secondary resistance. By comparing biopsies taken at baseline and at the time of disease progression, researchers found that recurrent mutations in the DNA repair gene SLX4 were present in 20% of resistant samples (4/20), compared to only 2% at baseline (2/88).

In vitro validation using siRNA knockdown confirmed that the loss of SLX4 function confers resistance to the DXd payload. This suggests that while HER2 expression determines initial drug delivery, the integrity of DNA repair pathways within the tumor cell is a key determinant of long-term sensitivity to the payload.

Conclusion

The DAISY trial confirms that HER2 expression is the primary determinant of T-DXd efficacy but highlights the drug's surprising activity in HER2 IHC 0 disease. The discovery of SLX4 mutations as a driver of resistance provides a novel biomarker for treatment failure and suggests that future therapeutic strategies might involve combining ADCs with DNA-repair inhibitors to overcome acquired resistance.

Summary updated

Abstract

<title>Abstract</title> Trastuzumab deruxtecan (T-DXd) is an anti-HER2 (human epidermal growth factor receptor 2) antibody-drug conjugate which has previously shown efficacy in patients with HER2-overexpressing and HER2-low metastatic breast cancer (mBC). However, the mechanisms of action and resistance of this drug remain partially unclear. DAISY (NCT04132960) is a phase II, open-label study that included patients with mBC whose disease progressed after at least one line of chemotherapy in the metastatic setting. Patients were enrolled in three cohorts according to HER2 expression determined by immunohistochemistry (IHC); cohort 1: HER2-overexpressing (HER2 IHC 3 + or HER2 IHC 2+/ISH+, <italic>n</italic> = 72), cohort 2: HER2-low (HER2 IHC2+/ISH- or HER2 IHC 1+, <italic>n</italic> = 74), and cohort 3: HER2 IHC 0 mBC (<italic>n</italic> = 40). Patients were treated with T-DXd 5.4 mg/kg every 3 weeks until disease progression or unacceptable toxicity. In the full analysis set population (<italic>n</italic> = 177), the confirmed objective response rate (ORR) was of 70.6% (95% CI: 58.3–81) in cohort 1, 37.5% (95% CI: 26.4–49.7) in cohort 2, and 29.7% (95% CI: 15.9–47) in cohort 3 (<italic>p</italic> &lt; 0.0001). The median progression-free survival (PFS) was 11.1 months (95% CI: 8.5–14.4) in cohort 1, 6.7 months (95% CI: 4.4–8.3) in cohort 2, and 4.2 months (95% CI: 2-5.7); in cohort 3. Cohort 1 was significantly associated with longer PFS (adjusted HR: 0.53, 95% IC: 0.34–0.84, <italic>p</italic> = 0.007), and cohort 3 with shorter PFS (adjusted HR: 1.96, 95% IC: 1.21–3.15, <italic>p</italic> = 0.006) as compared to cohort 2. Exploratory analyses showed that HER2 spatial distribution predicted T-DXd response in patients with HER2-overexpressing mBC and that the transcriptomic response to T-DXd was different according to HER2 expression. No quantitative modulation of tumor microenvironment was observed after 6 to 8 weeks of treatment. Finally, recurrent mutations of the DNA repair gene <italic>SLX4</italic> were identified in 20% of samples at resistance (4/20) as compared to 2% in baseline samples (2/88), suggesting that <italic>SLX4</italic> mutations could mediate secondary resistance to T-DXd. These data suggest that HER2 is a key determinant of T-DXd efficacy. However, an antitumor activity is also observed in a subgroup of patients without detectable HER2 expression and resistance could be partially mediated by payload sensitivity.
BibTeX
@inproceedings{andre2022mechanism,
  author = {Fabrice André and Fernanda Mosele and Élise Deluche and Amélie Lusque and Loic Le-Bescond and Thomas Filleron and Yoann Pradat and Agnès Ducoulombier and Barbara Pistilli and Thomas Bachelot and F. Viret and Christelle Lévy and Nicolas Signolle and Alexia Alfaro and D. Tran and Ingrid Garberis and Hugues Talbot and Stergios Christodoulidis and Maria Vakalopoulou and Nathalie Droin and Aurelie Stourm and Maki Kobayashi and Tomaya Kakegawa and Ludovic Lacroix and Patrick Saulnier and Bastien Job and Marc Deloger and Marta Jimenez and Vianney Baris and Pierre Laplante and Patricia Kannouche and Virginie Marty and Magali Lacroix‐Triki and Véronique Dièras},
  title = {{Mechanism of action and resistance to Trastuzumab Deruxtecan in patients with metastatic breast cancer: the DAISY trial}},
  booktitle = {Research Square},
  year = {2022},
  doi = {10.21203/rs.3.rs-2083650/v1},
}
Figure